NCT03706547 - Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

December 31, 2021

Conditions

Multiple Myeloma in RelapseMultiple Myeloma Progression

Interventions

BIOLOGICAL

anti-CD19/BCMA CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

300mg/m2/d

Trial Locations (1)

Department of Hematology ,Fudan University Zhongshan Hospital, Shanghai